Table 1 Demographic characteristics of the children analysed in this study
Variable | CR-GNB1 colonisation group (n = 69) | Control group (n = 138) | χ2 | P-value |
|---|---|---|---|---|
Age in months (median, range) | 61.0(38.5–132.0) | 72.0(48.0-132.0) | / | 0.739 |
Gender (male), n (%) | 42(60.9) | 80(58.0) | 0.160 | 0.689 |
AML/ALL2, n (%) | 65(94.2) | 112(81.2) | 6.135 | 0.012 |
Prior concomitant infections within the last 1 month, n (%) | 66(95.7) | 114(82.6) | 6.900 | 0.009 |
Sepsis | 58(84.1) | 101(73.2) | 3.051 | 0.081 |
Respiratory tract infection | 34(49.3) | 52(37.7) | 2.546 | 0.111 |
Enteritis | 8(11.6) | 16(11.6) | 0.000 | 1.000 |
Oral mucositis | 9(13.0) | 8(5.8) | 3.204 | 0.073 |
Prior β-lactam-β-lactamase inhibitor combinations usage within the last 1 month, n (%) | 21(30.4) | 52(37.7) | 1.058 | 0.304 |
Prior cephalosporins usage within the last 1 month, n (%) | 13(18.8) | 31(22.5) | 0.361 | 0.548 |
Prior 3rd generation cephalosporins usage within the last 1 month, n (%) | 13(18.8) | 30(21.7) | 0.235 | 0.628 |
Prior carbapenems usage within the last 1 month, n (%) | 50(72.5) | 68(49.3) | 10.092 | 0.001 |
Prior macrolides usage within the last 1 month, n (%) | 3(4.3) | 17(12.3) | 3.349 | 0.067 |
Prior sulfonamides usage within the last 1 month, n (%) | 19(27.5) | 34(24.6) | 0.203 | 0.652 |
Number of days since last chemotherapy(median, range) | 15.0(12.0–29.0) | 13.5(10.0-23.3) | / | 0.116 |
Prior HSCT3, n (%) | 11(15.9) | 4(2.9) | 11.644 | 0.001 |
WBCs, ×109/L (median, range) | 0.55(0.22–2.05) | 0.82(0.29–3.12) | / | 0.142 |
Platelets, ×109/L (median, range) | 44(17–72) | 40(17–127) | / | 0.619 |
CRP, mg/L (median, range) | 8.81(0.97–34.98) | 5.36(0.50-20.23) | / | 0.124 |
Agranulocytosis | 51(73.9) | 89(64.5) | 1.865 | 0.172 |
Outcomes, n (%) | ||||
CR-GNB3 infections | 8(11.6) | 3(2.2) | 6.349 | 0.012 |
Thirty-day mortality | 4(5.8) | 0(0.0) | 5.385 | 0.020 |